NASDAQ:ARNA
Delisted
Arena Pharmaceuticals Stock News
$99.99
+0 (+0%)
At Close: May 27, 2022
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the completion of its previously announced underwritten public offering of 6,325,000 shares of its common stock at a price to the public of $
Moving Average Crossover Alert: Arena Pharmaceuticals
01:30pm, Monday, 01'st Jun 2020
Arena Pharmaceuticals, Inc. (ARNA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
12:30pm, Thursday, 28'th May 2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $50.00 per share. All of t
The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer
12:00am, Thursday, 28'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 27)
ADC Therapeutics SA (NYSE:...
Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
08:01pm, Wednesday, 27'th May 2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $250,000,000 of its common
Arena Pharmaceuticals Announces $250M Proposed Public Offering of Common Stock
12:00am, Wednesday, 27'th May 2020Arena Completes Full Enrollment of Etrasimod Phase 2 ADVISE Trial for Atopic Dermatitis, Provides Program Updates
12:30pm, Tuesday, 26'th May 2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has completed full enrollment of the Phase 2b ADVISE trial evaluating etrasimod, an investigational next-generation, once-daily, oral
Arena Completes Full Enrollment Of Etrasimod Phase 2 ADVISE Trial For Atopic Dermatitis, Provides Program Updates
12:00am, Tuesday, 26'th May 2020Arena Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
08:30pm, Friday, 22'nd May 2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and lo
Jefferies Maintains Buy on Arena Pharmaceuticals, Raises Price Target to $69
12:00am, Friday, 22'nd May 2020Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:01pm, Wednesday, 20'th May 2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on May 15, 2020, the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 113,1
Galecto Appoints New Chair and Strengthens Board of Directors
08:10pm, Tuesday, 19'th May 2020
Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today that its Board of Directors has appointed Amit Munshi as
